• Je něco špatně v tomto záznamu ?

Bridging basic science and applied diagnostics: Comprehensive viral diagnostics enabled by graphene-based electronic biosensor technology advancements

AN. Herdina, A. Bozdogan, P. Aspermair, J. Dostalek, M. Klausberger, N. Lingg, M. Cserjan-Puschmann, PP. Aguilar, S. Auer, H. Demirtas, J. Andersson, F. Lötsch, B. Holzer, A. Steinrigl, F. Thalhammer, J. Schellnegger, M. Breuer, W. Knoll, R. Strassl

. 2025 ; 267 (-) : 116807. [pub] 20240921

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002915

Grantová podpora
P 35103 Austrian Science Fund FWF - Austria

This study presents a graphene field-effect transistor (gFET) biosensor with dual detection capabilities for SARS-CoV-2: one RNA detection assay to confirm viral positivity and the other for nucleocapsid (N-)protein detection as a proxy for infectiousness of the patient. This technology can be rapidly adapted to emerging infectious diseases, making an essential tool to contain future pandemics. To detect viral RNA, the highly conserved E-gene of the virus was targeted, allowing for the determination of SARS-CoV-2 presence or absence using nasopharyngeal swab samples. For N-protein detection, specific antibodies were used. Tested on 213 clinical nasopharyngeal samples, the gFET biosensor showed good correlation with RT-PCR cycle threshold values, proving its high sensitivity in detecting SARS-CoV-2 RNA. Specificity was confirmed using 21 pre-pandemic samples positive for other respiratory viruses. The gFET biosensor had a limit of detection (LOD) for N-protein of 0.9 pM, establishing a foundation for the development of a sensitive tool for monitoring active viral infection. Results of gFET based N-protein detection corresponded to the results of virus culture in all 16 available clinical samples and thus it also proved its capability to serve as a proxy for infectivity. Overall, these findings support the potential of the gFET biosensor as a point-of-care device for rapid diagnosis of SARS-CoV-2 infection and indirect assessment of infectiousness in patients, providing additional information for clinical and public health decision-making.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002915
003      
CZ-PrNML
005      
20250206103936.0
007      
ta
008      
250121e20240921enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bios.2024.116807 $2 doi
035    __
$a (PubMed)39341071
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Herdina, Anna Nele $u Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria
245    10
$a Bridging basic science and applied diagnostics: Comprehensive viral diagnostics enabled by graphene-based electronic biosensor technology advancements / $c AN. Herdina, A. Bozdogan, P. Aspermair, J. Dostalek, M. Klausberger, N. Lingg, M. Cserjan-Puschmann, PP. Aguilar, S. Auer, H. Demirtas, J. Andersson, F. Lötsch, B. Holzer, A. Steinrigl, F. Thalhammer, J. Schellnegger, M. Breuer, W. Knoll, R. Strassl
520    9_
$a This study presents a graphene field-effect transistor (gFET) biosensor with dual detection capabilities for SARS-CoV-2: one RNA detection assay to confirm viral positivity and the other for nucleocapsid (N-)protein detection as a proxy for infectiousness of the patient. This technology can be rapidly adapted to emerging infectious diseases, making an essential tool to contain future pandemics. To detect viral RNA, the highly conserved E-gene of the virus was targeted, allowing for the determination of SARS-CoV-2 presence or absence using nasopharyngeal swab samples. For N-protein detection, specific antibodies were used. Tested on 213 clinical nasopharyngeal samples, the gFET biosensor showed good correlation with RT-PCR cycle threshold values, proving its high sensitivity in detecting SARS-CoV-2 RNA. Specificity was confirmed using 21 pre-pandemic samples positive for other respiratory viruses. The gFET biosensor had a limit of detection (LOD) for N-protein of 0.9 pM, establishing a foundation for the development of a sensitive tool for monitoring active viral infection. Results of gFET based N-protein detection corresponded to the results of virus culture in all 16 available clinical samples and thus it also proved its capability to serve as a proxy for infectivity. Overall, these findings support the potential of the gFET biosensor as a point-of-care device for rapid diagnosis of SARS-CoV-2 infection and indirect assessment of infectiousness in patients, providing additional information for clinical and public health decision-making.
650    12
$a biosenzitivní techniky $x přístrojové vybavení $x metody $7 D015374
650    12
$a grafit $x chemie $7 D006108
650    12
$a SARS-CoV-2 $x izolace a purifikace $x genetika $7 D000086402
650    _2
$a lidé $7 D006801
650    12
$a COVID-19 $x diagnóza $x virologie $7 D000086382
650    12
$a RNA virová $x izolace a purifikace $x analýza $7 D012367
650    _2
$a limita detekce $7 D057230
650    _2
$a koronavirové nukleokapsidové proteiny $x izolace a purifikace $7 D000086462
650    _2
$a elektronické tranzistory $7 D014173
650    _2
$a fosfoproteiny $7 D010750
650    _2
$a nazofarynx $x virologie $7 D009305
650    _2
$a design vybavení $7 D004867
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bozdogan, Anil $u Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria; BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria
700    1_
$a Aspermair, Patrik $u BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria; Life Sciences Technology, Danube Privat University, Wiener Neustadt, Austria
700    1_
$a Dostalek, Jakub $u Life Sciences Technology, Danube Privat University, Wiener Neustadt, Austria; Institute of Physics, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Klausberger, Miriam $u Department of Biotechnology, BOKU University, Vienna, Austria
700    1_
$a Lingg, Nico $u ACIB - Austrian Centre of Industrial Biotechnology, Vienna, Austria; Department of Biotechnology, Institute of Bioprocess Science and Engineering, BOKU University, Vienna, Austria
700    1_
$a Cserjan-Puschmann, Monika $u ACIB - Austrian Centre of Industrial Biotechnology, Vienna, Austria; Department of Biotechnology, Institute of Bioprocess Science and Engineering, BOKU University, Vienna, Austria
700    1_
$a Aguilar, Patricia Pereira $u ACIB - Austrian Centre of Industrial Biotechnology, Vienna, Austria; Department of Biotechnology, Institute of Bioprocess Science and Engineering, BOKU University, Vienna, Austria
700    1_
$a Auer, Simone $u BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria
700    1_
$a Demirtas, Halil $u BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria
700    1_
$a Andersson, Jakob $u BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria; Institute of Science and Technology Austria, Klosterneuburg, Austria
700    1_
$a Lötsch, Felix $u Division of Clinical Microbiology, Medical University of Vienna, Vienna, Austria; Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria
700    1_
$a Holzer, Barbara $u Institute Krems Bioanalytics, IMC Krems University of Applied Sciences, Krems, Austria
700    1_
$a Steinrigl, Adi $u Austrian Agency for Health and Food Safety (AGES), Institute for Veterinary Disease Control Mödling, Mödling, Austria
700    1_
$a Thalhammer, Florian $u Department of Urology, Medical University of Vienna, Vienna, Austria
700    1_
$a Schellnegger, Julia $u Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria
700    1_
$a Breuer, Monika $u Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria
700    1_
$a Knoll, Wolfgang $u BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria; Life Sciences Technology, Danube Privat University, Wiener Neustadt, Austria
700    1_
$a Strassl, Robert $u Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria. Electronic address: Robert.strassl@meduniwien.ac.at
773    0_
$w MED00006627 $t Biosensors & bioelectronics $x 1873-4235 $g Roč. 267 (20240921), s. 116807
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39341071 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103932 $b ABA008
999    __
$a ok $b bmc $g 2262980 $s 1238922
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 267 $c - $d 116807 $e 20240921 $i 1873-4235 $m Biosensors & bioelectronics $n Biosens Bioelectron $x MED00006627
GRA    __
$a P 35103 $p Austrian Science Fund FWF $2 Austria
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace